Liver News and Research

RSS

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Marblar is gamifying the process of technology transfer. We post technology on our platform in the form of a challenge, and the Marblar community then competes to uncover new problems these technologies could solve – thereby discovering new market applications for these technologies.

31 Jan 2013

Study shows how gut microbes conspire with poor diets to trigger childhood malnutrition

A study of young twins in Malawi, in sub-Saharan Africa, finds that bacteria living in the intestine are an underlying cause of a form of severe acute childhood malnutrition.

31 Jan 2013

IL-13 protein could be the key to development of fibrosis in Crohn's disease

New research has shown that a protein, known as IL-13, could be the key to the development of fibrosis in Crohn's disease. This breakthrough could help to advance new medicines to treat people suffering with the disease.

30 Jan 2013

Tributyltin exposure may cause ‘transgenerational obesity’

Research shows that offspring of mice exposed to low doses of the chemical tributyltin, used in paints, plastics, and other consumer products, have greater than normal body fat, liver fat, and fat-specific gene expression.

30 Jan 2013

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for KYNAMROTM (mipomersen sodium) injection.

30 Jan 2013

Genzyme receives FDA approval for Kynamro to treat homozygous familial hypercholesterolemia

The U.S. Food and Drug Administration today approved Kynamro (mipomersen sodium) injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH).

30 Jan 2013

Scientists identify genetic process in which normal liver cells transform into cancerous ones

A team of scientists from the Cancer Science Institute of Singapore (CSI) at the National University of Singapore (NUS) has identified a genetic process in which normal liver cells transform into cancerous ones. The finding provides new understanding into the pathogenesis of human cancers.

29 Jan 2013

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 15 new Damon Runyon Fellows at its fall Fellowship Award Committee review.

29 Jan 2013

LOX enzyme can create scarred microenvironment that enhances cancer spreading

What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is a strong focus for cancer researchers.

28 Jan 2013

IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis

Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.

28 Jan 2013

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets.

28 Jan 2013

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

27 Jan 2013

Undetected comorbidities linked to increased mortality in schizophrenia

Patients with schizophrenia have elevated mortality, the leading causes of which appear to be ischemic heart disease and cancer, a Swedish national cohort study shows.

25 Jan 2013

Antibiotic use common at the end of life

More than one-quarter of hospice patients receive antibiotics in their last week of life, despite the absence of documented infection in most cases, US researchers report.

25 Jan 2013

Gastrointestinal, liver effects common after doxycycline in cats

Doxycycline, an antibiotic derivative of tetracycline, commonly results in adverse gastrointestinal side effects and increased liver enzyme activity in cats, report German researchers.

25 Jan 2013

Researchers identify cancer-associated mutations

Two new mutations that collectively occur in 71 percent of malignant melanoma tumors have been discovered in what scientists call the "dark matter" of the cancer genome, where cancer-related mutations haven't been previously found.

25 Jan 2013

Mice exposed to BPA exhibit spontaneous activity, have leaner body mass

Female mice exposed to Bisphenol A through their mother's diet during gestation and lactation were found to be hyperactive, exhibit spontaneous activity and had leaner body mass than those not exposed to the chemical, researchers at the University of Michigan School of Public Health have discovered.

25 Jan 2013

Early-life exposure to TBT chemical can cause obesity

Exposing pregnant mice to low doses of the chemical tributyltin (TBT) - which was used in marine antifouling paints and is used as an antifungal agent in some paints, certain plastics and a variety of consumer products - can lead to obesity for multiple generations without subsequent exposure, a UC Irvine study has found.

25 Jan 2013

Women taking tacrolimus drug can breast feed their babies

Women taking the immunosuppressant tacrolimus can rest assured that breast feeding will not elevate their babies' exposure to the drug, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

24 Jan 2013

Clinical trial to evaluate cyclodextrin against Niemann-Pick disease type C1

A clinical trial to evaluate a drug candidate called cyclodextrin as a possible treatment for Niemann-Pick disease type C1 (NPC), a rare and fatal genetic disease, will start today, researchers announced.

24 Jan 2013